A Phase 4 interventional study of JNJ-67896049 in Pulmonary Arterial Hypertension, sponsored by Actelion. Terminated at 35 sites in 15 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.
Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one is the 12th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 4, and was the 8th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:
Actelion · Sites in Belarus, Belgium, Bulgaria and 10 more countries
Ages 2+
By country, each count listing its studies:
selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 67 across the 12 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson: 2 open now, 5 under way, 2 of them phase 3. Of 55 finished, 33 (60%) have results posted.
Among the 63 studies in Pulmonary Arterial Hypertension by Johnson & Johnson, this one is the 45th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2021, is one of 11 in phase 4, and was the 56th registered.
Johnson & Johnson’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
1 of the studies testing selexipag in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 63 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive JNJ-67896049 tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
Drug: JNJ-67896049
Participants will receive tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
Also known as: Selexipag
Change From Baseline to Week 26 in Right Ventricular Stroke Volume (RVSV) Assessed by Pulmonary Artery Flow Magnetic Resonance Imaging (MRI)
Change from baseline to Week 26 in RVSV assessed by pulmonary artery flow MRI was reported.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in Right Ventricular End-Diastolic Volume (RVEDV) Assessed by MRI
Change from baseline to Week 26 in RVEDV assessed by MRI was reported.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in Right Ventricular End-Systolic Volume (RVESV) Assessed by MRI
Change from baseline to Week 26 in RVESV assessed by MRI was reported.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in Right Ventricular Ejection Fraction (RVEF) Assessed by MRI
Change from baseline to Week 26 in RVEF assessed by MRI was reported. RVEF was the fraction of the end-diastolic volume (EDV) that is ejected out of right ventricle with each contraction. EDV is the volume of blood within a ventricle immediately before a contraction.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in Right Ventricular (RV) Mass Index Assessed by MRI
Change from baseline to Week 26 in RV mass index assessed by MRI was reported.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in Right Ventricular Global Longitudinal Strain (RVGLS) Assessed by MRI
Change in RVGLS was a measure of longitudinal percent change in length of endocardium at Week 26 from baseline length assessed by MRI.
Time frame: Baseline, Week 26
Number of Participants With Change From Baseline to Week 26 in World Health Organization (WHO) Functional Class
WHO functional classification for PAH ranged from Class I (no limitation in physical activity, ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope), Class II (slight limitation of physical activity, ordinary physical activity cause undue dyspnea or fatigue, chest pain or near syncope), Class III (marked limitation of physical activity, less than ordinary activity cause undue dyspnea or fatigue, chest pain or near syncope) and Class IV (cannot perform a physical activity without any symptoms, dyspnea and/or fatigue may even be present at rest). Change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement =reduction in functional class; worsened =increase in functional class; and no change = no change in functional class.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in N-terminal-Pro-Hormone Brain Natriuretic Peptide (NT-proBNP)
NT pro-BNP is a cardiac biomarker that is released in the blood in response to changes in the pressure inside of the heart. Levels go up when heart failure develops or gets worse, and levels go down when heart failure is stable or improves. This biomarker helps to measure the changes in the severity of heart failure over time in response to therapy.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in 6-Minute Walk Distance (6MWD)
6MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.
Time frame: Baseline, Week 26
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product. Any AE occurring at or after the initial administration of study intervention up to 3 days after last dose of study intervention was considered as treatment-emergent.
Time frame: Day 1 up to 3 days after last dose of study drug (up to 52 weeks and 3 days that is 367 days)
Number of Participants With Adverse Events (AEs) Leading to Premature Discontinuation of Study Drug
Number of participants with AEs leading to premature discontinuation of study drug were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Time frame: Day 1 up to last dose of study drug (up to Week 52)
Number of Participants With Adverse Events of Special Interest (AESI)
Number of participants with AESI were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AESI were anaemia, bleeding events, gastrointestinal disturbances denoting intestinal intussusception (manifested as ileus or obstruction), hyperthyroidism, hypotension, light-dependent non-melanoma skin malignancies, major adverse cardiovascular events (MACE), medication errors, ophthalmological effects associated to retinal vascular system, pregnancy, pulmonary venoocclusive disease associated with pulmonary oedema, renal function impairment / acute renal failure.
Time frame: Day 1 up to 3 days after last dose of study drug (up to 52 weeks and 3 days that is 367 days)
Number of Participants With Treatment-Emergent Marked Laboratory Abnormalities
Number of participants with treatment-emergent marked laboratory abnormalities in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, creatinine, sodium, potassium, hemoglobin, hematocrit; EVF; PCV (male), hematocrit; EVF; PCV (female), platelets (assuming no platelet cluster), leukocytes; white blood cells, Neutrophils (Abs), Eosinophils (Abs), lymphocytes (Abs) were reported. Abnormalities that occurred after study treatment start and up to 3 days after study treatment discontinuation, that were not present at baseline, were treatment-emergent. Treatment-emergent marked laboratory abnormalities were determined at the investigator's discretion.
Time frame: Day 1 up to 3 days after last dose of study drug (up to 52 weeks and 3 days that is 367 days)
Change From Baseline to Week 26 in Number of Non-invasive Low-risk Criteria Among the 8 Variables
The risk score is derived for each participant considering the following non-invasive low-risk criteria among the 8 variables: absence of clinical signs of right heart failure, absence of symptoms progression, absence of syncope, WHO FC I-II, 6MWD greater than (\>) 440 meter, NT-proBNP less than (\<) 300 ng/L, Right atrial (RA) area \<18 centimeter square (cm\^2) as determined by echocardiography (Echo), absence of pericardial effusion, as determined by Echo. Number of low-risk criteria at baseline and Week 26 constitutes risk score and were derived for each participant by adding '1' for each of above criteria met. Number of low-risk criteria among the 8 variables for each participant can vary from 0 (worse participants) to 8 (healthier participants). Higher score indicated healthier participants.
Time frame: Baseline, Week 26
Change From Baseline to Week 26 in Number of Non-invasive Low-risk Criteria Among the 3 Variables
The risk score is derived for each participant considering the following non-invasive low-risk criteria among the 3 variables: WHO FC I-II, 6MWD \>440 m, NT-proBNP \< 300 ng/L. Number of low-risk criteria at baseline and Week 26 constitutes risk score and were derived for each participant by adding '1' for each of above criteria met. Number of low-risk criteria among the 3 variables for each participant can vary from 0 (worse participants) to 3 (healthier participants). Higher score indicated healthier participants.
Time frame: Baseline, Week 26
| Milestone | Selexipag |
|---|---|
| Started | 9 |
| Completed | 5 |
| Not completed | 4 |
| Withdrew: Study terminated by sponsor | 4 |
Change from baseline to Week 26 in RVSV assessed by pulmonary artery flow MRI was reported.
| Milliliter (mL) | Selexipag |
|---|---|
| Participant 1 | 38.35 |
| Participant 2 | -1.53 |
| Participant 3 | 16.53 |
| Participant 4 | 11 |
| Participant 5 | 27.2 |
| Participant 6 | 14.07 |
Change from baseline to Week 26 in RVEDV assessed by MRI was reported.
| Milliliter | Selexipag |
|---|---|
| Participant 1 | 40.57 |
| Participant 2 | -8.89 |
| Participant 3 | 23.58 |
| Participant 4 | 6.79 |
| Participant 5 | 3.71 |
| Participant 6 | 7.82 |
Change from baseline to Week 26 in RVESV assessed by MRI was reported.
| Milliliter | Selexipag |
|---|---|
| Participant 1 | 2.23 |
| Participant 2 | -7.36 |
| Participant 3 | 7.05 |
| Participant 4 | -4.22 |
| Participant 5 | -23.5 |
| Participant 6 | -6.25 |
Change from baseline to Week 26 in RVEF assessed by MRI was reported. RVEF was the fraction of the end-diastolic volume (EDV) that is ejected out of right ventricle with each contraction. EDV is the volume of blood within a ventricle immediately before a contraction.
| Percentage of EDV | Selexipag |
|---|---|
| Participant 1 | 9.65 |
| Participant 2 | 0.42 |
| Participant 3 | 6.96 |
| Participant 4 | 5.01 |
| Participant 5 | 19.12 |
| Participant 6 | 7.62 |
Change from baseline to Week 26 in RV mass index assessed by MRI was reported.
| Grams per meter square (g/m^2) | Selexipag |
|---|---|
| Participant 1 | -11.03 |
| Participant 2 | 2.72 |
| Participant 3 | -12.69 |
| Participant 4 | 0.09 |
| Participant 5 | -16.56 |
| Participant 6 | -2.41 |
Change in RVGLS was a measure of longitudinal percent change in length of endocardium at Week 26 from baseline length assessed by MRI.
| Percent change in length of endocardium | Selexipag |
|---|---|
| Participant 1: RVGLS Endocardium | -4.26 |
| Participant 2: RVGLS Endocardium | -5.31 |
| Participant 3: RVGLS Endocardium | -12.8 |
| Participant 4: RVGLS Endocardium | -5.61 |
| Participant 5: RVGLS Endocardium | -14.45 |
| Participant 6: RVGLS Endocardium | -1.74 |
WHO functional classification for PAH ranged from Class I (no limitation in physical activity, ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope), Class II (slight limitation of physical activity, ordinary physical activity cause undue dyspnea or fatigue, chest pain or near syncope), Class III (marked limitation of physical activity, less than ordinary activity cause undue dyspnea or fatigue, chest pain or near syncope) and Class IV (cannot perform a physical activity without any symptoms, dyspnea and/or fatigue may even be present at rest). Change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement =reduction in functional class; worsened =increase in functional class; and no change = no change in functional class.
| Participants | Selexipag |
|---|---|
| Baseline: Class I | 0 |
| Baseline: Class II | 4 |
| Baseline: Class III | 4 |
| Baseline: Class IV | 0 |
| Week 26: Improved | 3 |
| Week 26: Unchanged | 5 |
| Week 26: Worsened | 0 |
NT pro-BNP is a cardiac biomarker that is released in the blood in response to changes in the pressure inside of the heart. Levels go up when heart failure develops or gets worse, and levels go down when heart failure is stable or improves. This biomarker helps to measure the changes in the severity of heart failure over time in response to therapy.
| nanograms/liter (ng/L) | Selexipag |
|---|---|
| Participant 1 | -202.376 |
| Participant 2 | 142.9233 |
| Participant 3 | -261.4904 |
| Participant 4 | 78.6501 |
| Participant 5 | -215.8226 |
| Participant 6 | -762.5677 |
6MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.
| Meter | Selexipag |
|---|---|
| Participant 1 | -72 |
| Participant 2 | 0 |
| Participant 3 | 275 |
| Participant 4 | 14 |
| Participant 5 | 17 |
| Participant 6 | 16 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product. Any AE occurring at or after the initial administration of study intervention up to 3 days after last dose of study intervention was considered as treatment-emergent.
| Participants | Selexipag |
|---|---|
| AEs | 9 |
| SAEs | 1 |
Number of participants with AEs leading to premature discontinuation of study drug were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
| Participants | Selexipag |
|---|---|
| Number of Participants With Adverse Events (AEs) Leading to Premature Discontinuation of Study Drug | 0 |
Number of participants with AESI were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AESI were anaemia, bleeding events, gastrointestinal disturbances denoting intestinal intussusception (manifested as ileus or obstruction), hyperthyroidism, hypotension, light-dependent non-melanoma skin malignancies, major adverse cardiovascular events (MACE), medication errors, ophthalmological effects associated to retinal vascular system, pregnancy, pulmonary venoocclusive disease associated with pulmonary oedema, renal function impairment / acute renal failure.
| Participants | Selexipag |
|---|---|
| Number of Participants With Adverse Events of Special Interest (AESI) | 3 |
Number of participants with treatment-emergent marked laboratory abnormalities in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, creatinine, sodium, potassium, hemoglobin, hematocrit; EVF; PCV (male), hematocrit; EVF; PCV (female), platelets (assuming no platelet cluster), leukocytes; white blood cells, Neutrophils (Abs), Eosinophils (Abs), lymphocytes (Abs) were reported. Abnormalities that occurred after study treatment start and up to 3 days after study treatment discontinuation, that were not present at baseline, were treatment-emergent. Treatment-emergent marked laboratory abnormalities were determined at the investigator's discretion.
| Participants | Selexipag |
|---|---|
| Number of Participants With Treatment-Emergent Marked Laboratory Abnormalities | 3 |
The risk score is derived for each participant considering the following non-invasive low-risk criteria among the 8 variables: absence of clinical signs of right heart failure, absence of symptoms progression, absence of syncope, WHO FC I-II, 6MWD greater than (\>) 440 meter, NT-proBNP less than (\<) 300 ng/L, Right atrial (RA) area \<18 centimeter square (cm\^2) as determined by echocardiography (Echo), absence of pericardial effusion, as determined by Echo. Number of low-risk criteria at baseline and Week 26 constitutes risk score and were derived for each participant by adding '1' for each of above criteria met. Number of low-risk criteria among the 8 variables for each participant can vary from 0 (worse participants) to 8 (healthier participants). Higher score indicated healthier participants.
| Score on a scale | Selexipag |
|---|---|
| Participant 1 | 1 |
| Participant 2 | 1 |
| Participant 3 | 3 |
| Participant 4 | 1 |
| Participant 5 | 1 |
| Participant 6 | 1 |
The risk score is derived for each participant considering the following non-invasive low-risk criteria among the 3 variables: WHO FC I-II, 6MWD \>440 m, NT-proBNP \< 300 ng/L. Number of low-risk criteria at baseline and Week 26 constitutes risk score and were derived for each participant by adding '1' for each of above criteria met. Number of low-risk criteria among the 3 variables for each participant can vary from 0 (worse participants) to 3 (healthier participants). Higher score indicated healthier participants.
| Score on a scale | Selexipag |
|---|---|
| Participant 1 | 1 |
| Participant 2 | 0 |
| Participant 3 | 2 |
| Participant 4 | 1 |
| Participant 5 | 1 |
| Participant 6 | 1 |
Collected over All Cause Mortality: Day 1 up to 30 days after last dose of drug (up to Week 56), SAEs and non-SAEs: Day 1 up to 3 days after last dose of study drug (up to 52 weeks and 3 days that is 367 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selexipag | 0/9 (0%) | 1/9 (11.1%) | 9/9 (100%) |
| Event | Selexipag |
|---|---|
| Cardiac FailureCardiac disorders | 1/9 |
| Vaginal HaemorrhageReproductive system and breast disorders | 1/9 |
| Event | Selexipag |
|---|---|
| NauseaGastrointestinal disorders | 7/9 |
| HeadacheNervous system disorders | 6/9 |
| DiarrhoeaGastrointestinal disorders | 5/9 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/9 |
| Pain in JawMusculoskeletal and connective tissue disorders | 4/9 |
| Covid-19Infections and infestations | 3/9 |
| VomitingGastrointestinal disorders | 2/9 |
| Chest PainGeneral disorders | 2/9 |
| FatigueGeneral disorders | 2/9 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 2/9 |
| Age, Continuous(years) | Selexipag |
|---|---|
| Mean | 42.2 ± 13.28 |
| Age, Customized(Participants) | Selexipag |
|---|---|
| In utero | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 9 |
| From 65-84 years | 0 |
| 85 years and over | 0 |
| Sex: Female, Male(Participants) | Selexipag |
|---|---|
| Female | 6 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | Selexipag |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Selexipag |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 7 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 2 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Data sharing details ↗ · www.janssen.com
Ran from Jul 2021 to primary completion in Jul 2023, 24 months.
Results were first posted in Aug 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selexipag
Pulmonary Arterial Hypertension →